U.S. Food et al., 2016-10-19: FDA's approval letter granting Janssen's 500 mg chewable Vermox on 19 October 2016 through the 505(b)(2) pathway, i.e. relying on literature and prior findings rather than new proprietary clinical trials. It fixes the approval date and route for the 500 mg product.
Please refer to your New Drug Application (NDA) dated April 19, 2016, received April 19, 2016, and your amendments, submitted pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FDCA) for VERMOXTM Chewable (mebendazole chewable tablets), 500 mg.
p. 1
U.S. Food et al., 2016-10-19: FDA's approval letter granting Janssen's 500 mg chewable Vermox on 19 October 2016 through the 505(b)(2) pathway, i.e. relying on literature and prior findings rather than new proprietary clinical trials. It fixes the approval date and route for the 500 mg product. Federal record; letter dated 21 October 2016, approval effective 19 October 2016 (openFDA submission ORIG-1 status date 2016-10-19). The 505(b)(2) route is relevant to C2: no new Janssen formulation patent was located for the chewable 500 mg tablet, consistent with a literature-based application. No study data in the letter itself; the review documents sit at the NDA 208398 review index.
